Kathleen Kahler Fonda

Array ( [id] => 18420534 [patent_doc_number] => 20230174996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => REASSORTED ISA VIRUS [patent_app_type] => utility [patent_app_number] => 17/785223 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093419 [patent_doc_number] => 20220411760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => NOVEL VERO CELL LINE THAT CAN BE SUSPENSION-CULTURED IN SERUM-FREE MEDIUM, PREPARATION METHOD THEREFOR, AND METHOD FOR PREPARING VIRUSES FOR VACCINES BY USING NOVEL CELL LINE [patent_app_type] => utility [patent_app_number] => 17/780093 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497687 [patent_doc_number] => 20230220356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => COMPOSITIONS AND METHODS FOR PRODUCING A VIRAL VACCINE WITH REDUCED PARTICLE SIZE [patent_app_type] => utility [patent_app_number] => 17/771625 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19839080 [patent_doc_number] => 12251435 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Engineered Hansenula fungi efficiently expressing CA10 virus-like particles and uses thereof [patent_app_type] => utility [patent_app_number] => 17/299520 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 8361 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17836483 [patent_doc_number] => 20220273788 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => VACCINE [patent_app_type] => utility [patent_app_number] => 17/628286 [patent_app_country] => US [patent_app_date] => 2020-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17628286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527501 [patent_doc_number] => 12545928 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Machine methods to determine neoepitope payload toxicity [patent_app_type] => utility [patent_app_number] => 17/633876 [patent_app_country] => US [patent_app_date] => 2020-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 3 [patent_no_of_words] => 0 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17633876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20534501 [patent_doc_number] => 12551552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => Antigenic glycoprotein E polypeptides, compositions, and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/626206 [patent_app_country] => US [patent_app_date] => 2020-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 12589 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17626206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830409 [patent_doc_number] => 20220267713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => METHOD FOR PRODUCING VIRUS AND HARVEST LIQUID COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/596732 [patent_app_country] => US [patent_app_date] => 2020-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720784 [patent_doc_number] => 20220213504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => Zika Virus Constructs and Therapeutic Compositions Thereof [patent_app_type] => utility [patent_app_number] => 17/609496 [patent_app_country] => US [patent_app_date] => 2020-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17673026 [patent_doc_number] => 20220186193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => METHODS AND COMPOSITIONS FOR IMPROVING THE ASSEMBLY OF ADENO-ASSOCIATED VIRUSES (AAVs) [patent_app_type] => utility [patent_app_number] => 17/603221 [patent_app_country] => US [patent_app_date] => 2020-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17603221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17838053 [patent_doc_number] => 20220275358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => METHODS OF SIZE EXCLUSION CHROMATOGRAPHY FOR THE CHARACTERIZATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/602199 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18019092 [patent_doc_number] => 20220370591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => COMPOSITIONS COMPRISING NUCLEIC ACIDS ENCODING STRUCTURAL TRIMERS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/601412 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20687705 [patent_doc_number] => 12617840 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-05 [patent_title] => Hybridoma cell line for secreting anti-rabies virus M protein monoclonal antibody and application thereof [patent_app_type] => utility [patent_app_number] => 17/294414 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 0 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18406064 [patent_doc_number] => 20230167415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-01 [patent_title] => A LIVE AND ATTENUATED FLAVIVIRUS COMPRISING A MUTATED M PROTEIN [patent_app_type] => utility [patent_app_number] => 17/593446 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17593446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655455 [patent_doc_number] => 20220175920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => RECOMBINANT PROTEINS WITH CD40 ACTIVATING PROPERTIES [patent_app_type] => utility [patent_app_number] => 17/598582 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17598582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17928445 [patent_doc_number] => 20220323570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => HIGHLY NETWORKED IMMUNOGEN COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/437470 [patent_app_country] => US [patent_app_date] => 2020-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17437470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609907 [patent_doc_number] => 20220152186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => NOROVIRUS-LIKE PARTICLES WITH IMPROVED STABILITY [patent_app_type] => utility [patent_app_number] => 17/438047 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17438047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484953 [patent_doc_number] => 20230212268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => FILOVIRUS ANTIBODIES AND METHODS [patent_app_type] => utility [patent_app_number] => 17/436782 [patent_app_country] => US [patent_app_date] => 2020-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7963 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17436782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609912 [patent_doc_number] => 20220152191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => METHOD FOR PREPARING INFLUENZA HA SPLIT VACCINE [patent_app_type] => utility [patent_app_number] => 17/435590 [patent_app_country] => US [patent_app_date] => 2020-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20076293 [patent_doc_number] => 12350328 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses [patent_app_type] => utility [patent_app_number] => 17/434489 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 24578 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434489 [rel_patent_id] =>[rel_patent_doc_number] =>)